Quality of life in ovarian cancer patients: Comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study

Journal of Clinical Oncology

Volumn 22, Issue 22, 2004, Pages 4595-4603

  Bezjak, Andrea ^a   Tu, Dongsheng ^a   Bacon, Monica ^a   Osoba, David ^a   Zee, Benny ^a   Stuart, Gavin ^a   Roy, Josee Anne ^a   Piccart, Martine ^a   Eisenhauer, Elizabeth ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL; ANTINEOPLASTIC AGENT;

ABDOMINAL CRAMP; ABDOMINAL SWELLING; ADVANCED CANCER; APPETITE DISORDER; ARTICLE; CANCER PATIENT; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FATIGUE; HUMAN; MUSCLE DISEASE; MYALGIA; NEUROTOXICITY; OVARY CANCER; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; ABDOMINAL PAIN; ADULT; AGED; APPETITE; CARCINOMA; COMPARATIVE STUDY; EMOTION; FEMALE; HEALTH STATUS; MIDDLE AGED; MULTICENTER STUDY; OVARY TUMOR; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PSYCHOLOGICAL ASPECT; SLEEP; SOCIAL SUPPORT; SURVIVAL;

ABDOMINAL PAIN; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APPETITE; CARCINOMA; CISPLATIN; CYCLOPHOSPHAMIDE; EMOTIONS; FEMALE; HEALTH STATUS; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; QUALITY OF LIFE; SLEEP; SOCIAL SUPPORT; SURVIVAL ANALYSIS;

EID: 16544365861     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.08.080     Document Type: Article

References (22)

1. Advanced Ovarian Cancer Trialists Group: Chemotherapy for advanced ovarian cancer, in The Cochrane Library Issue 2, Chichester, UK, John Wiley and Sons Ltd, 2004
2. The Ovarian Cancer Meta-Analysis Project: Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin and cisplatin chemotherapy of ovarian carcinoma: A meta-analysis. J Clin Oncol 9:1668-1674, 1991
3. Covens A, Carey M, Bryson P, et al: Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer. Gynecol Oncol 85:71-80, 2002
4. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996
5. Piccart MJ, Bertelsen K, James K, et al: Randomized Intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced ovarian cancer. J Natl Cancer Inst 92:699-708, 2000
6. Muggia FM, Braly PS, Brady MF, et al: Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol 18:106-115, 2000
7. The International Collaborative Ovarian Neoplasm (ICON) Group: Paclitaxel plus carboplatin versus standard chemotherapy with either single agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial. Lancet 360:505-515, 2002
8. Montazeri A, McEwan J, Gillis CR: Quality of life in patients with ovarian cancer: Current state research. Support Care Cancer 4:169-179, 1996
9. Bezjak A: Quality of life in women with cancer, in Kabanagh J, Singletary E, Einhorn N, et al (eds): Cancer in Women. Malden, MA, Blackwell, 1998, pp 610-632
10. Schink JC, Weller E, Harris LS, et al: Outpatient Taxol and carboplatin chemotherapy for suboptimally debulked epithelial carcinoma of the ovary results in improved quality of life: An Eastern Cooperative Oncology Group phase II study (E2E93). Cancer J 7:155-164, 2001
11. Lakusta CM, Atkinson MJ, Robinson JW, et al: Quality of life in ovarian cancer patients receiving chemotherapy. Gynecol Oncol 81:490-495, 2001
12. Holzner B, Kemmler G, Meranger V, et al: Fatigue in ovarian carcinoma patients: A neglected issue? Cancer 97:1564-1572, 2003
13. Wenzel LB, Donnelly JP, Fowler JM, et al: Resilience, reflection, and residual stress in ovarian cancer survivorship: A Gynecologic Oncology Group study. Psychooncology 11:142-153, 2002
14. Du Bois A, Luck H-J, Meier W, et al: A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95:1320-1330, 2003
15. Piccart M, Bertelsen K, Stuart G, et al: Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Ann Oncol 13:109, 2002 (suppl 5)
16. Osoba D, Zee B, Pater J, et al: Psychometric properties and responsiveness of EORTC Quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res 3:353-364, 1994
17. Fayers P, Aaronson N, Bjordal K, et al: EORTC Scoring Manual (ed 2). Brussels, Belgium, EORTC Quality of Life Study Group, 1999
18. Zee B: Growth curve model analysis for quality of life data. Stat Med 17:757-766, 1998
19. Bacon M, James K, Zee B: A comparison of the incidence, duration and degree of the neurological toxicities of cisplatin-paclitaxel (PT) and cisplatin-cyclophosphamide (PC). Int J Gynecol Cancer 13:428-434, 2003
20. Geels P, Eisenhauer E, Bezjak A, et al: The palliative effect of chemotherapy: Objective tumor response correlates with symptom improvement in patients with metastatic breast cancer. J Clin Oncol 18:2395-2405, 2000
21. Ozols RF, Bundy BN, Fowler J, et al: Randomized phase III study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO)/PAC in optimal stage III epithelial ovarian cancer (OC): A Gynecologic Oncology Group Trial (GOG 158). Proc Am Soc Clin Oncol 18:356a, 1999 (abstr 1373)
22. Neijt JP, Engelholm SA, Tuxen MK, et al: Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 18:3084-3092, 2000